Ironwood Pharmaceuticals Inc (IRWD):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Ironwood Pharmaceuticals Inc (IRWD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9773)・商品コード:DATA904C9773
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:77
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal disorders. The company’s major products include Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in adults; Zurampic (lesinurad) and Duzallo (lesinurad and allopurinol), for the treatment of hyperuricemia associated with gout. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions including IBS-C or CIC in pediatrics, abdominal pain associated with IBS and uncontrolled gastroesophageal reflux disease. Its other product candidates are intended for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and specialty diseases, including sickle cell disease and achalasia. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc (IRWD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11
Nicox Enters into Agreement with Ironwood Pharma 12
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15
Licensing Agreements 17
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 17
Equity Offering 18
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 18
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 19
Ironwood Pharma Completes Partial Exercise Of Underwriter’s Option For Public Offering Of Shares For US$146 Million 21
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 23
Debt Offering 25
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 25
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 26
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 27
Ironwood Pharmaceuticals Inc – Key Competitors 29
Ironwood Pharmaceuticals Inc – Key Employees 30
Ironwood Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 06, 2018: Ironwood Pharmaceuticals provides second quarter 2018 investor update 32
May 01, 2018: Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update 37
Feb 15, 2018: Ironwood Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 39
Nov 02, 2017: Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update 42
Aug 03, 2017: Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update 47
May 08, 2017: Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update 49
Feb 21, 2017: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update 51
Corporate Communications 55
Nov 28, 2017: Ironwood Pharmaceuticals Strengthens Executive Leadership Team 55
Sep 06, 2017: Ironwood Pharmaceuticals Announces Leadership Change 56
Apr 06, 2017: Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer 57
Jan 04, 2017: Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors 58
Government and Public Interest 59
May 01, 2018: Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business 59
Clinical Trials 61
Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718 61
Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018 62
May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week 2018 64
Dec 21, 2017: Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease 66
Dec 04, 2017: Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects 67
Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease 69
May 01, 2017: Ironwood Pharmaceuticals to Present New Data for IW-1701 at Digestive Disease Week 2017 71
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-1973 at R&D Day 2017 72
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017 73
Other Significant Developments 74
May 01, 2018: Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action 74
Jan 08, 2017: Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech 75
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11
Nicox Enters into Agreement with Ironwood Pharma 12
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 17
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 18
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 19
Ironwood Pharma Completes Partial Exercise Of Underwriter's Option For Public Offering Of Shares For US$146 Million 21
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 23
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 25
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 26
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 27
Ironwood Pharmaceuticals Inc, Key Competitors 29
Ironwood Pharmaceuticals Inc, Key Employees 30
Ironwood Pharmaceuticals Inc, Subsidiaries 31

List of Figures
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Ironwood Pharmaceuticals Inc (IRWD):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9773)販売に関する免責事項を必ずご確認ください。
★調査レポート[Ironwood Pharmaceuticals Inc (IRWD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆